Non Hodgkin Lymphoma clinical trials

Explore recruiting non hodgkin lymphoma clinical trials.

Recruiting non hodgkin lymphoma studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Non Hodgkin Lymphoma trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Randomized, Double-Blind, Multicenter, Placebo-Controlled Phase 3 Study of Orelabrutinib in Combination with Rituximab and Bendamustine (BR) vs. BR in Subjects with Treatment-Naїve Mantle Cell Lymphoma

Poland, France, Czechia, Spain, Romania

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Single Arm, Open-Label, Phase 1b Trial of Epcoritamab in Pediatric Patients with Relapsed/ Refractory Aggressive Mature B-cell Neoplasms

Italy, Germany, Czechia, Spain, France, Belgium

Human Pharmacology (Phase I)- Other EU CTIS Study details

An Adaptive Phase 3, Randomized, Open-Label, Multicenter Study to Compare the Efficacy and Safety of Axicabtagene Ciloleucel versus Standard of Care Therapy as First-Line Therapy in Subjects with High-Risk Large B-Cell Lymphoma (ZUMA-23)

Austria, Italy, Germany, France, Netherlands, Portugal +1 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 3 Randomized Double-Blind Multicenter Study of Sonrotoclax Plus Zanubrutinib Versus Placebo Plus Zanubrutinib in Patients With Relapsed/Refractory Mantle Cell Lymphoma

Germany, France, Italy, Poland, Spain, Austria

Therapeutic confirmatory (Phase III) EU CTIS Study details

Glo-BNHL: A Global Study of Novel Agents in Paediatric and Adolescent Relapsed and Refractory B-cell Non-Hodgkin Lymphoma

Austria, Belgium, Netherlands, Sweden, France, Spain

Phase II and Phase III (Integrated) EU CTIS Study details

Tisagenlecleucel versus standard of care in adult patients with relapsed or refractory aggressive B-cell non-Hodgkin lymphoma: A randomized, open label, phase III trial (BELINDA)

Netherlands, Spain, Norway, Italy, Germany, France +1 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Non Hodgkin Lymphoma trials by city

Non Hodgkin Lymphoma in Toronto Non Hodgkin Lymphoma in Vancouver Non Hodgkin Lymphoma in Montreal Non Hodgkin Lymphoma in Calgary Non Hodgkin Lymphoma in Edmonton Non Hodgkin Lymphoma in Ottawa Non Hodgkin Lymphoma in Winnipeg Non Hodgkin Lymphoma in Quebec City Non Hodgkin Lymphoma in Hamilton Non Hodgkin Lymphoma in Kitchener Non Hodgkin Lymphoma in London Non Hodgkin Lymphoma in Halifax Non Hodgkin Lymphoma in New York Non Hodgkin Lymphoma in Los Angeles Non Hodgkin Lymphoma in Chicago Non Hodgkin Lymphoma in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease